ReviewTranslational andrology and urology2018
Ultra-small superparamagnetic iron oxide contrast agents for lymph node staging of high-risk prostate cancer.
Review in Translational andrology and urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 28 citations in OpenAlex.
- Contrast Agents in Breast MRI: State of the Art and Future Perspectives.Biomedicines · 2025Review
- Integration of magnetic resonance imaging and deep learning for prostate cancer detection: a systematic review.American journal of clinical and experimental urology · 2025Review
- Future Directions in the Assessment of Axillary Lymph Nodes in Patients with Breast Cancer.Medicina (Kaunas, Lithuania) · 2023Review
- Staging of Prostate Cancer: Role of Multiparametric Magnetic Resonance Imaging in Different Risk Classes.Urology research & practice · 2023Article
- Cell Proliferation, Viability, Differentiation, and Apoptosis of Iron Oxide Labeled Stem Cells Transfected with Lipofectamine Assessed by MRI.Journal of clinical medicine · 2023Article
- Management of Bladder Cancer Patients with Clinical Evidence of Lymph Node Invasion (cN+).Cancers · 2022Review
- MRI tracking of human Wharton's jelly stem cells seeded onto acellular dermal matrix labeled with superparamagnetic iron oxide nanoparticles in burn wounds.Burns & trauma · 2022Article
- Management of Clinically Regional Node-Positive Urothelial Carcinoma of the Bladder.Current oncology reports · 2021Review
- Article
- MRI tracing of ultrasmall superparamagnetic iron oxide nanoparticle‑labeled endothelial progenitor cells for repairing atherosclerotic vessels in rabbits.Molecular medicine reports · 2020Article
- Imaging diagnosis of metastatic breast cancer.Insights into imaging · 2020Review
- MRI-Tracking of Dental Pulp Stem Cells In Vitro and In Vivo Using Dextran-Coated Superparamagnetic Iron Oxide Nanoparticles.Journal of clinical medicine · 2019Article
- Imaging of distant metastases of prostate cancer.Medical oncology (Northwood, London, England) · 2018Review
- Target Volume Optimization for Localized Prostate Cancer.Practical radiation oncologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
Ultrasmall superparamagnetic particles of iron oxide (USPIOs) imaged with magnetic resonance imaging (MRI) have been proposed as an experimental method for visualizing lymph node (LN) metastases. The method does not require ionizing radiation, yet can detect small nodes that are involved with metastases. USPIOs are naturally taken up by macrophages that deposit in the normal LN creating a low signal region in normal areas; areas within the node that do not show this loss of signal are likely involved by tumor although there can be other causes (fibrosis or inflammation). However, the lack of approved USPIOs that are clinically available hinders adoption and larger studies. The proposed indications for USPIO MRI, including specific compounds and imaging methods are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.